Abstract | BACKGROUND: METHODS: RESULTS: A total of 996 patients were included in the primary analysis (40-mg laninamivir octanoate, n = 334; 20-mg laninamivir octanoate, n = 326; and oseltamivir, n = 336). The median time to illness alleviation in the 40-mg laninamivir octanoate, 20-mg laninamivir octanoate, and oseltamivir groups was 73.0, 85.8, and 73.6 h, respectively. The difference between laninamivir octanoate and oseltamivir was -0.6 h (95% confidence interval, -9.9 to 6.9 h) for the 40-mg group and 12.2 h (95% confidence interval, -1.5 to 17.2 h) for the 20-mg group. The upper limits of the 95% confidence intervals were less than the prespecified noninferiority margin (18 h). The proportion of patients shedding virus at day 3 was significantly lower in the 40-mg laninamivir octanoate group than in the oseltamivir group (P = .006). CONCLUSIONS: CLINICAL TRIALS REGISTRATION: NCT00803595.
|
Authors | Akira Watanabe, Shan-Chwen Chang, Min Ja Kim, Daniel Wai-Sing Chu, Yasuo Ohashi, MARVEL Study Group |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 51
Issue 10
Pg. 1167-75
(Nov 15 2010)
ISSN: 1537-6591 [Electronic] United States |
PMID | 20936975
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Guanidines
- Pyrans
- Sialic Acids
- Oseltamivir
- laninamivir
- Zanamivir
|
Topics |
- Administration, Inhalation
- Administration, Oral
- Adult
- Aged
- Antiviral Agents
(administration & dosage)
- Drug Administration Schedule
- Female
- Guanidines
- Humans
- Influenza A Virus, H1N1 Subtype
(isolation & purification)
- Influenza A Virus, H3N2 Subtype
(isolation & purification)
- Influenza B virus
(isolation & purification)
- Influenza, Human
(drug therapy, virology)
- Male
- Middle Aged
- Oseltamivir
(administration & dosage)
- Pyrans
- Sialic Acids
- Viral Load
- Zanamivir
(administration & dosage, analogs & derivatives)
|